PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Serr, I. ; Drost, F.* ; Schubert, B. ; Daniel, C.

Antigen-specific Treg therapy in type 1 diabetes - challenges and opportunities.

Front. Immunol. 12:712870 (2021)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Regulatory T cells (Tregs) are key mediators of peripheral self-tolerance and alterations in their frequencies, stability, and function have been linked to autoimmunity. The antigen-specific induction of Tregs is a long-envisioned goal for the treatment of autoimmune diseases given reduced side effects compared to general immunosuppressive therapies. However, the translation of antigen-specific Treg inducing therapies for the treatment or prevention of autoimmune diseases into the clinic remains challenging. In this mini review, we will discuss promising results for antigen-specific Treg therapies in allergy and specific challenges for such therapies in autoimmune diseases, with a focus on type 1 diabetes (T1D). We will furthermore discuss opportunities for antigen-specific Treg therapies in T1D, including combinatorial strategies and tissue-specific Treg targeting. Specifically, we will highlight recent advances in miRNA-targeting as a means to foster Tregs in autoimmunity. Additionally, we will discuss advances and perspectives of computational strategies for the detailed analysis of tissue-specific Tregs on the single-cell level.
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
7.561
1.573
4
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter T1d ; Tcr Specificity Prediction ; Antigen-specific Treg Therapy ; Autoimmunity ; Micrornas ; Single-cell Multi-omics Integration ; Tissue Tregs; Regulatory T-cells; Oral Insulin; High-risk; Expression; Immunotherapy; Heterogeneity; Autoimmunity; Prevention; Induction; Landscape
Sprache englisch
Veröffentlichungsjahr 2021
HGF-Berichtsjahr 2021
ISSN (print) / ISBN 1664-3224
e-ISSN 1664-3224
Zeitschrift Frontiers in Immunology
Quellenangaben Band: 12, Heft: , Seiten: , Artikelnummer: 712870 Supplement: ,
Verlag Frontiers
Verlagsort Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Type 1 Diabetes Immunology (TDI)
Institute of Computational Biology (ICB)
POF Topic(s) 30201 - Metabolic Health
30205 - Bioengineering and Digital Health
Forschungsfeld(er) Helmholtz Diabetes Center
Enabling and Novel Technologies
PSP-Element(e) G-502191-001
G-503800-001
Förderungen EFSD/JDRF/Lilly Programme on Type 1 Diabetes Research 2020
German Center for Diabetes Research (DZD)
Research Group at Helmholtz Zentrum Munchen
Helmholtz Association
Helmholtz Association under the joint research school "Munich School for Data Science
Deutsche Forschungsgemeinschaft (DFG)
Helmholtz Zentrum Munchen
DOI 10.3389/fimmu.2021.712870
WOS ID WOS:000689519900001
Scopus ID 85112591573
PubMed ID 34367177
Erfassungsdatum 2021-09-15
[➜Korrektur melden]